Page contents Key factsDecisionRelated medicine informationTopicsKey facts Invented name Vargatef; OfevVargatefOfev Active Substance nintedanib Therapeutic area Oncology Decision number P/0124/2017 PIP number EMEA-001006-PIP03-16 Pharmaceutical form(s) Capsule (soft) Condition(s) / indication(s) Treatment of lung carcinoma (small cell and non-small cell carcinoma)Treatment of mesothelioma Route(s) of administration Oral use Contact for public enquiries Boehringer Ingelheim International GmbHTel. +49 6132 778271Email: Paediatrics@boehringer-ingelheim.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 05/05/2017DecisionP/0124/2017: EMA decision of 5 May 2017 on the granting of a product-specific waiver for nintedanib (Vargatef, Ofev), (EMEA-001006-PIP03-16)AdoptedReference Number: EMA/260237/2017 English (EN) (71.03 KB - PDF)First published: 03/07/2017Last updated: 03/07/2017ViewRelated medicine informationVargatefOfevTopicsPaediatricsShare this page